[
  {
    "ts": null,
    "headline": "Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'",
    "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
    "url": "https://finnhub.io/api/news?id=11bf0d0ac31355a22d9f2e26aec905187c2805243413bef511b34506b5ef54ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731342803,
      "headline": "Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake'",
      "id": 131286640,
      "image": "",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
      "url": "https://finnhub.io/api/news?id=11bf0d0ac31355a22d9f2e26aec905187c2805243413bef511b34506b5ef54ee"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie tumbles on drug test disappointment, Bristol-Myers gains",
    "summary": "AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
    "url": "https://finnhub.io/api/news?id=f187fb376e4dbbaf610b7babf95f352644c8762c3e84b3084a27c7871b5d8ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731357937,
      "headline": "AbbVie tumbles on drug test disappointment, Bristol-Myers gains",
      "id": 131292299,
      "image": "https://s.yimg.com/ny/api/res/1.2/xk9OudErYJqsN1gk_gSl6w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-10/8b2797a0-a06a-11ef-baed-fe04858da93c",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AbbVie (ABBV) shares slide after its schizophrenia drug failed to meet the goals of its mid-stage trial. Shares of Bristol-Myers Squibb (BMY), a competitor which makes a similar drug, have jumped. Market Domination Hosts Julie Hyman and Josh Lipton outline what investors need to know. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.",
      "url": "https://finnhub.io/api/news?id=f187fb376e4dbbaf610b7babf95f352644c8762c3e84b3084a27c7871b5d8ab0"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?",
    "summary": "BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.",
    "url": "https://finnhub.io/api/news?id=c3f876ff1bd010701d315180b9c48ee001e9b59871422e9182c4e1dbbaf4410c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731351000,
      "headline": "Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?",
      "id": 131295862,
      "image": "https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more room for growth, and any dip in share price can be used as a buying opportunity.",
      "url": "https://finnhub.io/api/news?id=c3f876ff1bd010701d315180b9c48ee001e9b59871422e9182c4e1dbbaf4410c"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
    "summary": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=c441ec3b88aebad43670a46fdf2a5952c3e0b6be7214e24073fec0939936a6e7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731345840,
      "headline": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
      "id": 131414144,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Health Care Down as AbbVie, Humana Weigh -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=c441ec3b88aebad43670a46fdf2a5952c3e0b6be7214e24073fec0939936a6e7"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint",
    "summary": "Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.",
    "url": "https://finnhub.io/api/news?id=de6b158fbf81d2149cfa73df997524b97838cc663d755e529ed9c3794f7c133d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731345512,
      "headline": "AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint",
      "id": 131294144,
      "image": "https://www.investopedia.com/thmb/1uMmEvMuPuVPhD-BtI7GlCLn9Zg=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2172784450-f3019c75fc0a4b74954a38833c0a69ca.jpg",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.",
      "url": "https://finnhub.io/api/news?id=de6b158fbf81d2149cfa73df997524b97838cc663d755e529ed9c3794f7c133d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ad9888ca2e8a0bceaa2065f93302342a45c32e9a08ba1a9698e8c24a8171297b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731343380,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 131417109,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ad9888ca2e8a0bceaa2065f93302342a45c32e9a08ba1a9698e8c24a8171297b"
    }
  },
  {
    "ts": null,
    "headline": "On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned",
    "summary": "Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.",
    "url": "https://finnhub.io/api/news?id=b9c38fb503b1f28212c7249ba5817363351ebd99c2270eed4d34bccde3e86507",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731341652,
      "headline": "On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned",
      "id": 131294149,
      "image": "https://imgproxy.divecdn.com/1VkJByYLAsooqXJ6u2spJOeSb21aNeJte2QlVj9upgs/g:nowe:0:457/c:1333:753/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FiYlZpZV9CYXlfQXJlYV8wOTAyLmpwZw==.webp",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a better bet in buying Karuna Therapeutics.",
      "url": "https://finnhub.io/api/news?id=b9c38fb503b1f28212c7249ba5817363351ebd99c2270eed4d34bccde3e86507"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ETCompany...",
    "url": "https://finnhub.io/api/news?id=8ef6dc60287c66e2ff7c0000cb5e1922973463e0c650b3c51bc04bb97467f493",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731341284,
      "headline": "Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)",
      "id": 131291103,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ETCompany...",
      "url": "https://finnhub.io/api/news?id=8ef6dc60287c66e2ff7c0000cb5e1922973463e0c650b3c51bc04bb97467f493"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.",
    "summary": "Shares of  AbbVie  were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms.  The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (improvement)” on a widely used scale, compared to the placebo group at week six, according to a press release from the company.  The study examined patients who were experiencing acute exacerbation of psychotic symptoms.",
    "url": "https://finnhub.io/api/news?id=011c4f3cee24d94abdd07f2c602f8fc31e5425e85edbb0bab02f4e09cac04775",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731340020,
      "headline": "AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps.",
      "id": 131286377,
      "image": "https://s.yimg.com/ny/api/res/1.2/wIw1SYJSvVmuZxyb68GMZg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/Barrons.com/e6469760d530dff947ae3095e80a61aa",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of  AbbVie  were getting hammered Monday after the drug maker said two Phase 2 trials of its experimental schizophrenia drug showed no significant improvement in symptoms.  The drug, emraclidine, didn’t meet its “primary endpoint of showing a statistically significant reduction (improvement)” on a widely used scale, compared to the placebo group at week six, according to a press release from the company.  The study examined patients who were experiencing acute exacerbation of psychotic symptoms.",
      "url": "https://finnhub.io/api/news?id=011c4f3cee24d94abdd07f2c602f8fc31e5425e85edbb0bab02f4e09cac04775"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails",
    "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
    "url": "https://finnhub.io/api/news?id=bdf22112f2735aa8c8152e44e2095fc88bd88c6d4f873c2f7d52cc6906355fff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731337943,
      "headline": "Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails",
      "id": 131286378,
      "image": "",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.",
      "url": "https://finnhub.io/api/news?id=bdf22112f2735aa8c8152e44e2095fc88bd88c6d4f873c2f7d52cc6906355fff"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
    "summary": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
    "url": "https://finnhub.io/api/news?id=95544b6e5cc679023c3c27ee2ab7ee3dd8f67de4d693d92569204a1e2f1d6c6c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731337740,
      "headline": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
      "id": 131414147,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial",
      "url": "https://finnhub.io/api/news?id=95544b6e5cc679023c3c27ee2ab7ee3dd8f67de4d693d92569204a1e2f1d6c6c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Slides on Schizophrenia Drug Study Failure",
    "summary": "AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said Monday.",
    "url": "https://finnhub.io/api/news?id=7bfbeca807ba61f68da682aea98f93e1d6076fb3f8426def77fbc20b3985d7a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731335960,
      "headline": "AbbVie Stock Slides on Schizophrenia Drug Study Failure",
      "id": 131286379,
      "image": "https://s.yimg.com/ny/api/res/1.2/UvgsJ1xjhB7u4X.YMCVoAA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/wsj.com/7c682c3888a014bf4f80de294a8db9b9",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock sharply lower. Phase 2 studies for emraclidine failed to show a statistically significant improvement in symptoms after six weeks, the biopharmaceutical company said Monday.",
      "url": "https://finnhub.io/api/news?id=7bfbeca807ba61f68da682aea98f93e1d6076fb3f8426def77fbc20b3985d7a3"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie shares slip after schizophrenia drug trial misses primary endpoint",
    "summary": "Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.",
    "url": "https://finnhub.io/api/news?id=fc5fc287e2a9656aacedd378e05a86e041c393c8853f44203448205e126668f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731334670,
      "headline": "AbbVie shares slip after schizophrenia drug trial misses primary endpoint",
      "id": 131286381,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com - AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US trading.",
      "url": "https://finnhub.io/api/news?id=fc5fc287e2a9656aacedd378e05a86e041c393c8853f44203448205e126668f1"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024",
    "summary": "PRINCETON, N.J., November 11, 2024--Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Evidence Data at AHA 2024",
    "url": "https://finnhub.io/api/news?id=593d8fc6c3b7bfcedf3046715ab11b9357802b39173a7a8280260c63c24c3ab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731326340,
      "headline": "Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024",
      "id": 131286382,
      "image": "https://s.yimg.com/ny/api/res/1.2/Of6mZSKkMQht7DHN9j2g3g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD0xNjU-/https://media.zenfs.com/en/business-wire.com/4c2453f18c560c3bc5bcc5e671d1bc51",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., November 11, 2024--Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Evidence Data at AHA 2024",
      "url": "https://finnhub.io/api/news?id=593d8fc6c3b7bfcedf3046715ab11b9357802b39173a7a8280260c63c24c3ab0"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver",
    "summary": "AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.",
    "url": "https://finnhub.io/api/news?id=c039e5d2d8a619182815b5454087e3a92e1987c15e340bdf9dbe24ae4a4a2e7f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731325754,
      "headline": "AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver",
      "id": 131286787,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1726514483/image_1726514483.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.",
      "url": "https://finnhub.io/api/news?id=c039e5d2d8a619182815b5454087e3a92e1987c15e340bdf9dbe24ae4a4a2e7f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies",
    "summary": "Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.",
    "url": "https://finnhub.io/api/news?id=a79e6f1e9530a1b67b605fcd89472433b685a3a5580c2e87dc4e60aa82c73d34",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731325500,
      "headline": "AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies",
      "id": 131288234,
      "image": "https://imgproxy.divecdn.com/o3rQRIkPk1DZsOCoe7Z26lDhYDdnd60L-p1a4qmgADs/g:nowe:0:106/c:2000:1129/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0FiYlZpZV9CYXlfQXJlYV8wNTYxLmpwZw==.webp",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two Phase 2 trials.",
      "url": "https://finnhub.io/api/news?id=a79e6f1e9530a1b67b605fcd89472433b685a3a5580c2e87dc4e60aa82c73d34"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: data to be presented at the AHA",
    "summary": "Bristol Myers Squibb announces that it will present data from its cardiovascular portfolio at the American Heart Association's Annual Scientific Sessions, to be held November 16-18 in...",
    "url": "https://finnhub.io/api/news?id=4c54110ac781bca2d4491c631c6dd27df7bf48bf18bcf8ce250e91a1696e4287",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731310517,
      "headline": "Bristol Myers: data to be presented at the AHA",
      "id": 131283910,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Bristol Myers Squibb announces that it will present data from its cardiovascular portfolio at the American Heart Association's Annual Scientific Sessions, to be held November 16-18 in...",
      "url": "https://finnhub.io/api/news?id=4c54110ac781bca2d4491c631c6dd27df7bf48bf18bcf8ce250e91a1696e4287"
    }
  }
]